Johnson & Johnson Blog | Talkmarkets | Page 1
No data available
No data available

People who follow this stock (128)

Latest Posts

About This Stock More About This Stock
EC HH The Active Versus Passive Performance Debate Is Nonsensical
Article By: Chuck Carnevale
Thursday, May 18, 2017 10:23 AM EDT
One of the most hotly contested debates in finance is the argument over which is better – active or passive investing.
In this article: KMB, SPX, SO, JNJ
Read
Stock Valuation Johnson And Johnson
Article By: Andreas Gruener
Monday, May 8, 2017 2:31 PM EDT
Event though JNJ is always a very good investment I personally think that it is currently overvalued at its current price.
In this article: JNJ
Read
April Dividend Income Summary
Article By: Dividend Diplomats
Monday, May 8, 2017 1:47 PM EDT
It is always nice to see what changes your portfolio had over the last twelve months, which seems like a long period of time but somehow flies by.
In this article: PG, JNJ, IBM
Read
Prem Watsa’s Dividend Stock Portfolio: Every Holding Analyzed
Article By: SureDividend
Tuesday, May 2, 2017 2:56 AM EDT
As the Chief Executive Officer of Fairfax Financial Holdings Ltd., Watsa is the portfolio manager for an impressive sum of insurance float. Let's analyze Prem Watsa’s dividend stock investment portfolio in detail.
In this article: GD, HP, IBM, JNJ, KW, LUK, MON, NOV, PFE, PKX, USB, VAL, WFC, BWINB, NTES, RYAM Also: BRK-A, BRK-B, FRFHF
Read
Premarket Biotech Digest – BDX Finalizes Acquisition Deal, VNLPF Receives CRL, EYEG Files S-1
Article By: KKD Healthcare Analytics
Monday, April 24, 2017 10:03 AM EDT
Johnson & Johnson announced results from a Phase 2 clinical trial assessing the triple combination ofOlysio (simeprevir), C.R. Bard Inc. and Becton Dickinson finalize the deal for buying Bard.
In this article: BCR, JNJ, MRK, NVO, VNLPF, XOMA, EYEG, ARGNF, BDX
Read

PARTNER HEADLINES

Latest Tweets for $JNJ

No tweets yet!